PURE Bioscience is a company developing and commercializing antimicrobial products. It develops a technology platform based on stabilized ionic silver and products containing silver dihydrogen citrate (SDC). In addition, the Company manufactures and distributes SDC-based disinfecting and sanitizing products. It produces and supplies SDC-based formulations for the production of personal care products.
Type | Public | |
Founded | 1992 | |
HQ | Rancho Cucamonga, CA, US | Map |
Website | purebio.com |
USD | |
---|---|
Revenue (Q1, 2021) | 1.6m |
Gross profit (Q1, 2021) | 950.0k |
Gross profit margin (Q1, 2021), % | 59.7% |
Net income (Q1, 2021) | (180.0k) |
EBIT (Q1, 2021) | (179.0k) |
Market capitalization (15-Jan-2021) | 72.0m |
Closing stock price (15-Jan-2021) | 0.8 |
Cash (31-Oct-2020) | 3.5m |
USD | Q1, 2012 | Q2, 2012 | Q3, 2012 | Q1, 2013 | Q2, 2013 | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 257.0k | 221.0k | 207.0k | 110.0k | 263.0k | 258.0k | 115.0k | 41.0k | 261.0k | 117.0k | 273.0k | 109.0k | 186.0k | 176.0k | 403.0k | 531.0k | 447.0k | 338.0k | 464.0k | 411.0k | 390.0k | 590.0k | 394.0k | 312.0k | 398.0k | 349.0k | 2.2m | 1.6m |
Cost of goods sold | 129.0k | 40.0k | 37.0k | 31.0k | 57.0k | 67.0k | 36.0k | 20.0k | 89.0k | 45.0k | 111.0k | 65.0k | 54.0k | 48.0k | 116.0k | 265.0k | 134.0k | 132.0k | 146.0k | 161.0k | 166.0k | 203.0k | 160.0k | 117.0k | 156.0k | 142.0k | 972.0k | 641.0k |
Gross profit | 128.0k | 181.0k | 170.0k | 79.0k | 206.0k | 191.0k | 79.0k | 21.0k | 172.0k | 72.0k | 162.0k | 44.0k | 132.0k | 128.0k | 287.0k | 266.0k | 313.0k | 206.0k | 318.0k | 250.0k | 224.0k | 387.0k | 234.0k | 195.0k | 242.0k | 207.0k | 1.2m | 950.0k |
Gross profit Margin, % | 50% | 82% | 82% | 72% | 78% | 74% | 69% | 51% | 66% | 62% | 59% | 40% | 71% | 73% | 71% | 50% | 70% | 61% | 69% | 61% | 57% | 66% | 59% | 63% | 61% | 59% | 56% | 60% |
USD | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 |
---|---|---|---|---|---|---|---|---|---|
Cash | 877.0k | 32.0k | 86.0k | 1.3m | 5.2m | 1.6m | 851.0k | 398.0k | 3.8m |
Accounts Receivable | 373.0k | 18.0k | 47.0k | 189.0k | 263.0k | 297.0k | 275.0k | 373.0k | 1.1m |
Prepaid Expenses | 347.0k | 71.0k | 96.0k | 187.0k | 174.0k | 58.0k | 18.0k | 16.0k | |
Inventories | 654.0k | 365.0k | 249.0k | 207.0k | 350.0k | 273.0k | 197.0k | 177.0k | 547.0k |
USD | Q1, 2012 | Q2, 2012 | Q3, 2012 | Q1, 2013 | Q2, 2013 | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 992.0k | 626.0k | 289.0k | 2.5m | 920.0k | 410.0k | 1.1m | 236.0k | 416.0k | 5.3m | 3.9m | 2.5m | 6.1m | 6.7m | 5.4m | 4.1m | 3.9m | 2.7m | 3.2m | 2.1m | 1.0m | 776.0k | 335.0k | 340.0k | 904.0k | 246.0k | 2.0m | 3.5m |
Accounts Receivable | 119.0k | 16.0k | 193.0k | 64.0k | 95.0k | 29.0k | 31.0k | 9.0k | 34.0k | 47.0k | 40.0k | 86.0k | 93.0k | 106.0k | 68.0k | 146.0k | 142.0k | 185.0k | 143.0k | 146.0k | 192.0k | 353.0k | 129.0k | 134.0k | 220.0k | 156.0k | 1.6m | 560.0k |
Prepaid Expenses | 189.0k | 482.0k | 432.0k | 80.0k | 85.0k | 110.0k | 231.0k | 221.0k | 194.0k | 154.0k | 75.0k | 33.0k | 150.0k | 88.0k | 312.0k | 331.0k | 189.0k | 154.0k | 175.0k | 104.0k | 52.0k | 71.0k | 49.0k | 28.0k | 30.0k | 15.0k | 10.0k | 46.0k |
Inventories | 850.0k | 889.0k | 901.0k | 864.0k | 836.0k | 781.0k | 430.0k | 429.0k | 387.0k | 231.0k | 186.0k | 207.0k | 219.0k | 237.0k | 320.0k | 348.0k | 340.0k | 348.0k | 274.0k | 267.0k | 275.0k | 209.0k | 205.0k | 195.0k | 162.0k | 141.0k | 282.0k | 733.0k |
USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 |
---|---|---|---|---|---|---|---|---|
Net Income | (7.7m) | (11.0m) | (7.6m) | (14.4m) | (6.3m) | (7.4m) | (6.6m) | 4.0k |
Depreciation and Amortization | 311.0k | 248.0k | 206.0k | 219.0k | 276.0k | 285.0k | 241.0k | 192.0k |
Inventories | 149.0k | (12.0k) | 42.0k | (143.0k) | 27.0k | 37.0k | 20.0k | (370.0k) |
Accounts Payable | 962.0k | (96.0k) | (955.0k) | (131.0k) | (59.0k) | 103.0k | (40.0k) | 774.0k |
USD | Q1, 2012 | Q2, 2012 | Q3, 2012 | Q1, 2013 | Q2, 2013 | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 | Q1, 2021 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | (2.4m) | (4.6m) | (1.8m) | (2.2m) | (4.0m) | (5.5m) | (3.8m) | (6.3m) | (8.4m) | (1.9m) | (3.7m) | (5.8m) | (2.8m) | (13.7m) | (13.7m) | (1.7m) | (2.7m) | (4.4m) | (2.3m) | (4.4m) | (6.1m) | (2.6m) | (3.9m) | (5.7m) | (1.1m) | (1.8m) | (1.3m) | (180.0k) |
Depreciation and Amortization | 117.0k | 216.0k | 73.0k | 158.0k | 236.0k | 73.0k | 140.0k | 196.0k | 51.0k | 103.0k | 154.0k | 51.0k | 103.0k | 154.0k | 65.0k | 134.0k | 204.0k | 71.0k | 142.0k | 213.0k | 71.0k | 143.0k | 191.0k | 52.0k | 100.0k | 145.0k | 45.0k | |
Inventories | 11.0k | (28.0k) | (3.0k) | 25.0k | 80.0k | (65.0k) | (64.0k) | (22.0k) | 18.0k | 63.0k | 42.0k | (12.0k) | (30.0k) | (113.0k) | 2.0k | 10.0k | 2.0k | (1.0k) | (20.0k) | 17.0k | (12.0k) | (8.0k) | 2.0k | 15.0k | 36.0k | (105.0k) | (186.0k) | |
Accounts Payable | 438.0k | 935.0k | 209.0k | 234.0k | 487.0k | 42.0k | (275.0k) | (588.0k) | (955.0k) | (1.0m) | (1.1m) | (250.0k) | (33.0k) | (125.0k) | 147.0k | (36.0k) | 58.0k | (38.0k) | 7.0k | (52.0k) | (206.0k) | (128.0k) | (255.0k) | 139.0k | (46.0k) | 753.0k | (606.0k) |
USD | Q1, 2012 |
---|---|
Financial Leverage | 1.5 x |
When was PURE Bioscience founded?
PURE Bioscience was founded in 1992.
Who are PURE Bioscience key executives?
PURE Bioscience's key executives are Tom Y. Lee, Mark Elliott and Tom Myers.
How many employees does PURE Bioscience have?
PURE Bioscience has 10 employees.
What is PURE Bioscience revenue?
Latest PURE Bioscience annual revenue is $6.9 m.
What is PURE Bioscience revenue per employee?
Latest PURE Bioscience revenue per employee is $691.7 k.
Who are PURE Bioscience competitors?
Competitors of PURE Bioscience include Biosan Laboratories, 2XL and Peptilogics.
Where is PURE Bioscience headquarters?
PURE Bioscience headquarters is located at 9669 Hermosa Ave, Rancho Cucamonga.
Where are PURE Bioscience offices?
PURE Bioscience has offices in Rancho Cucamonga and El Cajon.
How many offices does PURE Bioscience have?
PURE Bioscience has 3 offices.
Receive alerts for 300+ data fields across thousands of companies